

# Pascal Furet

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11928803/pascal-furet-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120  
papers

9,840  
citations

53  
h-index

98  
g-index

135  
ext. papers

10,805  
ext. citations

6.1  
avg, IF

5.26  
L-index

#	Paper	IF	Citations
120	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 1851-63	6.1	1006
119	In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. <i>Cancer Cell</i> , <b>2004</b> , 5, 231-9	24.3	468
118	Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinases. <i>Journal of Medicinal Chemistry</i> , <b>2011</b> , 54, 7066-83	8.3	310
117	Strategies toward the design of novel and selective protein tyrosine kinase inhibitors <b>1999</b> , 82, 195-206		290
116	Characterization of the novel and specific PI3K $\beta$ inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1117-29	6.1	288
115	Tyrosine kinase inhibitors: from rational design to clinical trials. <i>Medicinal Research Reviews</i> , <b>2001</b> , 21, 499-512	14.4	283
114	Polyclonal Secondary Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 252-263	24.4	262
113	Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2013</b> , 23, 3741-8	2.9	259
112	The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. <i>Nature</i> , <b>2017</b> , 543, 733-737	50.4	256
111	Protein kinases as targets for anticancer agents: from inhibitors to useful drugs <b>2002</b> , 93, 79-98		253
110	Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. <i>Journal of Medicinal Chemistry</i> , <b>2000</b> , 43, 3205-8	8.3	230
109	Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. <i>FEBS Journal</i> , <b>1995</b> , 234, 317-22		222
108	New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. <i>Journal of Medicinal Chemistry</i> , <b>2000</b> , 43, 2310-23	8.3	207
107	Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 2656-62	8.3	206
106	Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. <i>Nature Structural Biology</i> , <b>1996</b> , 3, 586-9		205
105	Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. <i>Journal of Medicinal Chemistry</i> , <b>1997</b> , 40, 3601-16	8.3	187
104	Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. <i>Acta Crystallographica Section D: Biological Crystallography</i> , <b>2007</b> , 63, 80-93		180

103	Extended kinase profile and properties of the protein kinase inhibitor nilotinib. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , <b>2010</b> , 1804, 445-53	4	175
102	Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. <i>Cancer Research</i> , <b>2004</b> , 64, 6385-9	10.1	158
101	Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 8120-8135	8.3	144
100	Inhibition of cyclin-dependent kinase 4 (Cdk4) by faspaplysin, a marine natural product. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 275, 877-84	3.4	142
99	Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. <i>Mini-Reviews in Medicinal Chemistry</i> , <b>2004</b> , 4, 285-99 <sup>3.2</sup>		139
98	A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. <i>Journal of Molecular Biology</i> , <b>2000</b> , 299, 245-53	6.5	135
97	4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. <i>Journal of Medicinal Chemistry</i> , <b>1996</b> , 39, 2285-92	8.3	132
96	Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). <i>Biochemical Journal</i> , <b>2003</b> , 374, 639-46 <sup>2.8</sup>		127
95	Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 6348-58	8.3	111
94	Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , <b>2004</b> , 1697, 17-27 <sup>4</sup>		110
93	Total synthesis and biological evaluation of the nakijiquinones. <i>Journal of the American Chemical Society</i> , <b>2001</b> , 123, 11586-93	16.4	105
92	Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 5687-93	8.3	97
91	A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. <i>Cancer Research</i> , <b>2011</b> , 71, 5255-64 <sup>10.1</sup>		95
90	Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 1945-55	6.1	91
89	Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 436-46	9.7	91
88	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 1018-26	8.3	88
87	The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. <i>Angiogenesis</i> , <b>2010</b> , 13, 259-67	10.6	87
86	Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 1741-7	8.3	87

85	Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain. <i>Journal of Medicinal Chemistry</i> , <b>1998</b> , 41, 3442-9	8.3	86
84	Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2008</b> , 18, 1027-30	2.9	84
83	Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. <i>Journal of Medicinal Chemistry</i> , <b>1994</b> , 37, 1015-27	8.3	83
82	Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. <i>Journal of the American Chemical Society</i> , <b>2010</b> , 132, 7043-8	16.4	78
81	2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1999</b> , 9, 91-6	2.9	71
80	Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. <i>Journal of Computer-Aided Molecular Design</i> , <b>1995</b> , 9, 465-72	4.2	63
79	Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3164-3175	12.9	60
78	The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2012</b> , 22, 3498-502	2.9	60
77	Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2003</b> , 13, 2967-71	2.9	60
76	Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain. <i>Journal of Medicinal Chemistry</i> , <b>1997</b> , 40, 3551-6	8.3	59
75	Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. <i>BMC Chemical Biology</i> , <b>2009</b> , 9, 1		58
74	Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 8812-21	5.4	58
73	Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2004</b> , 14, 5793-7	2.9	58
72	A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. <i>ELife</i> , <b>2015</b> , 4,	8.9	57
71	Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor. <i>European Journal of Medicinal Chemistry</i> , <b>2004</b> , 39, 11-26	6.8	55
70	Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands. <i>Journal of Molecular Biology</i> , <b>1998</b> , 279, 1013-22	6.5	54
69	Selective GRB2 SH2 inhibitors as anti-Ras therapy. <i>International Journal of Cancer</i> , <b>1999</b> , 83, 235-41	7.5	54
68	Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 4810-3	8.3	53

67	Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , <b>2010</b> , 1804, 454-62	4	51
66	Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 2358-63	8.3	51
65	Entry into a new class of protein kinase inhibitors by pseudo ring design. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2008</b> , 18, 897-900	2.9	49
64	The TEAD4-YAP/TAZ protein-protein interaction: expected similarities and unexpected differences. <i>ChemBioChem</i> , <b>2013</b> , 14, 1218-25	3.8	47
63	Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2016</b> , 26, 4837-4841	2.9	47
62	Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO <sub>3</sub> H <sub>2</sub> )-X+1-Asn-NH <sub>2</sub> . <i>Journal of Medicinal Chemistry</i> , <b>1998</b> , 41, 1741-4	8.3	46
61	Effect of potent and selective inhibitors of the Grb2 SH2 domain on cell motility. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 23311-5	5.4	44
60	Structure-based design and protein X-ray analysis of a protein kinase inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2002</b> , 12, 221-4	2.9	43
59	Highly potent inhibitors of the Grb2-SH2 domain. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1999</b> , 9, 221-6	2.9	42
58	Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands. <i>Biochemistry</i> , <b>1997</b> , 36, 5712-8	3.2	41
57	Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2015</b> , 25, 3621-5	2.9	39
56	Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2009</b> , 19, 4014-7	2.9	39
55	Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201. <i>Cancer Research</i> , <b>2018</b> , 78, 6257-6267	10.1	38
54	Verification of a designed intramolecular hydrogen bond in a drug scaffold by nuclear magnetic resonance spectroscopy. <i>Journal of Medicinal Chemistry</i> , <b>2007</b> , 50, 5875-7	8.3	37
53	FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 2194-2206	6.1	35
52	Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 2609-13	2.9	34
51	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , <b>2016</b> , 7, 762-7	4.3	33
50	Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2001</b> , 11, 1321-4	2.9	31

49	Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. <i>FEBS Letters</i> , <b>2002</b> , 529, 293-7	3.8	30
48	Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2014</b> , 24, 2110-4	2.9	29
47	2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4. <i>ACS Medicinal Chemistry Letters</i> , <b>2018</b> , 9, 215-220	4.3	28
46	Structure-based design of potent CDK1 inhibitors derived from olomoucine. <i>Journal of Computer-Aided Molecular Design</i> , <b>2000</b> , 14, 403-9	4.2	28
45	New synthesis of oxcarbazepine via remote metalation of protected N-o-tolyl-anthranilamide derivatives. <i>Tetrahedron Letters</i> , <b>2001</b> , 42, 385-389	2	27
44	A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 132-46	8.3	26
43	Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. <i>Journal of Medicinal Chemistry</i> , <b>2006</b> , 49, 4451-4	8.3	26
42	Mapping the X(+1) binding site of the Grb2-SH2 domain with alpha,alpha-disubstituted cyclic alpha-amino acids. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1999</b> , 9, 2915-20	2.9	26
41	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. <i>Blood</i> , <b>2008</b> , 112, 5161-70	2.2	25
40	Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. <i>Future Medicinal Chemistry</i> , <b>2009</b> , 1, 137-55	4.1	24
39	Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2002</b> , 12, 1331-4	2.9	24
38	Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1998</b> , 8, 2865-70	2.9	23
37	Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. <i>Genes and Cancer</i> , <b>2010</b> , 1, 1021-32	2.9	22
36	Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 12542-12573	8.3	20
35	Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2007</b> , 17, 358-62	2.9	19
34	Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region. <i>MedChemComm</i> , <b>2017</b> , 8, 1604-1613	5	18
33	Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction. <i>Methods in Molecular Biology</i> , <b>2009</b> , 575, 173-94	1.4	18
32	X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2003</b> , 3, 15-23		18



31	2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 1724-7	2.9	17
30	Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2000</b> , 10, 2337-41	2.9	17
29	Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>1999</b> , 9, 1973-8	2.9	17
28	Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery. <i>Angewandte Chemie - International Edition</i> , <b>2016</b> , 55, 16026-16030	16.4	15
27	New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 3628-31	2.9	15
26	Discovery of a novel tricyclic 4H-thiazolo[5,4-b]pyrido[2,3-c]pyridine-2-amino scaffold and its application in a PI3K inhibitor with high PI3K isoform selectivity and potent cellular activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2015</b> , 25, 3582-4	2.9	14
25	Coupling of the antenapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2001</b> , 11, 2161-4	2.9	14
24	Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2015</b> , 25, 3575-81	2.9	13
23	Identification and optimisation of a 4R5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2015</b> , 25, 3569-74	2.9	13
22	STI571: A New Treatment Modality for CML?. <i>ACS Symposium Series</i> , <b>2001</b> , 245-259	0.4	13
21	Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy. <i>FEBS Journal</i> , <b>2019</b> , 286, 2381-2398	5.7	12
20	Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface. <i>Protein Science</i> , <b>2018</b> , 27, 1810-1820	6.3	12
19	Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors. <i>Protein Science</i> , <b>2020</b> , 29, 509-520	6.3	11
18	In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2018</b> , 28, 3404-3408	2.9	10
17	Convergent synthesis of potent peptide inhibitors of the Grb2-SH2 domain by palladium catalyzed coupling of a terminal alkyne. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2001</b> , 11, 1201-3	2.9	10
16	Identification of cyclin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching. <i>Journal of Computer-Aided Molecular Design</i> , <b>2001</b> , 15, 489-95	4.2	10
15	Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes. <i>ChemMedChem</i> , <b>2019</b> , 14, 1305-1314	3.7	9
14	Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy. <i>Biochemistry</i> , <b>2018</b> , 57, 5576-5590	3.2	9

13	Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2000</b> , 10, 2343-6	2.9	9
12	p53 dynamics vary between tissues and are linked with radiation sensitivity. <i>Nature Communications</i> , <b>2021</b> , 12, 898	17.4	9
11	Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2016</b> , 26, 2065-7	2.9	8
10	Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 1858-60	2.9	7
9	Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2016</b> , 26, 2057-64	2.9	6
8	A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors. <i>Scientific Reports</i> , <b>2020</b> , 10, 17442	4.9	4
7	Abstract 1797: Discovery of NVP-CGM097, a highly potent and optimized small molecule inhibitor of Mdm2 under evaluation in a Phase I clinical trial <b>2014</b> ,		3
6	Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery. <i>Angewandte Chemie</i> , <b>2016</b> , 128, 16260-16264	3.6	3
5	Prospects for Antiangiogenic Therapies Based upon VEGF Inhibition. <i>ACS Symposium Series</i> , <b>2001</b> , 282-298	2.4	2
4	Author response: A distinct p53 target gene set predicts for response to the selective p53-MDM2 inhibitor NVP-CGM097 <b>2015</b> ,		2
3	Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukemia. <i>NATO Science for Peace and Security Series A: Chemistry and Biology</i> , <b>2009</b> , 37-61	0.1	1
2	Potent Grb2-SH2 antagonists containing asparagine mimetics <b>2002</b> , 573-575		
1	Novel, Potent and Selective JAK2 Inhibitors.. <i>Blood</i> , <b>2009</b> , 114, 3777-3777	2.2	